US Broker Ratings

Abbott Laboratories (ABT) Stock Analysis: A Healthy Outlook with a 6.87% Upside

Abbott Laboratories (NYSE: ABT) stands as a formidable player in the healthcare sector, specializing in medical devices. With a market capitalization of $194.62 billion, this American healthcare giant is renowned..

Takeda Pharmaceutical Company L (TAK) Stock Analysis: Target Price Suggests a 21.41% Upside Potential

Takeda Pharmaceutical Company Limited (NYSE: TAK) stands as a formidable presence in the healthcare sector, specifically within the specialty and generic drug manufacturing industry. With its roots stretching back to..

CVS Health Corporation (CVS) Stock Analysis: A 24.74% Potential Upside with Strong Analyst Support

Investors eyeing opportunities in the healthcare sector should take a closer look at CVS Health Corporation (NYSE: CVS), a titan in the healthcare plans industry. With a formidable market capitalization..

Gilead Sciences, Inc. (GILD) Stock Analysis: Exploring Growth Potential Amidst a Robust 8.05% Upside

Gilead Sciences, Inc. (NASDAQ: GILD) stands as a formidable player in the healthcare sector, specifically within the drug manufacturing industry. With a market capitalization of $180.64 billion, this biopharmaceutical giant..

McKesson Corporation (MCK) Stock Analysis: Evaluating a 10.47% Potential Upside for Healthcare Investors

McKesson Corporation (NYSE: MCK), a titan in the healthcare sector, continues to captivate investor interest with its robust market presence and promising financial outlook. With a current market capitalization of..

Eli Lilly (LLY) Stock Analysis: Navigating Strong Revenue Growth and a $1.05 Trillion Market Cap

Eli Lilly and Company (NYSE: LLY) stands as a formidable player in the healthcare sector, boasting a market capitalization of $1.05 trillion. Specializing in the discovery, development, and marketing of..

Pfizer, Inc. (PFE) Stock Analysis: Is the 6.15% Dividend Yield a Golden Opportunity for Investors?

Pfizer, Inc. (NYSE: PFE), standing as a titan in the healthcare sector, has long been a staple in the portfolios of many investors. Known for its comprehensive range of biopharmaceutical..

Vertex Pharmaceuticals (VRTX) Stock Analysis: Is a 3.96% Upside Worth the Investment?

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), a heavyweight in the biotechnology sector, continues to captivate investor attention with its robust market position and innovative therapeutic offerings. With a market capitalization of..

AstraZeneca PLC (AZN) Stock Analysis: Unraveling a 30.63% Potential Upside Within the Healthcare Sector

AstraZeneca PLC (AZN), a prominent global player in the biopharmaceutical industry, presents a compelling opportunity for investors with its robust pipeline of prescription medicines and strategic partnerships. As a leading..

Danaher Corporation (DHR) Stock Report: Analyst Ratings Signal Strong Buy Potential

Danaher Corporation (NYSE: DHR), a heavyweight in the diagnostics and research industry, is making waves in the healthcare sector. With a robust market capitalization of $151.89 billion, the company operates..

UnitedHealth Group (UNH) Stock Analysis: A Healthcare Titan with 20.94% Potential Upside

UnitedHealth Group Incorporated (NYSE: UNH), a stalwart in the healthcare plans industry, commands a formidable presence with a market capitalization of $352.71 billion. As a leader in healthcare services, UnitedHealth..

PPHE Hotel Group appoints Yoav Papouchado as Non-Executive Director

PPHE Hotel Group has appointed Yoav Papouchado as a non-executive director and said it will review the Board’s overall composition and balance...

Nuvalent, Inc. (NUVL) Stock Analysis: Evaluating Growth Potential Amidst a Steady Market Position

Nuvalent, Inc. (NASDAQ: NUVL), a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, is making waves in the healthcare sector with its innovative approach to cancer treatment. As the company continues..

Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Is the 17.55% Potential Upside Worth the Risk?

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a prominent player in the biotechnology sector, is renowned for its focus on developing RNA-targeted therapeutics and genetic therapies aimed at treating rare diseases. With..

Inspire Medical Systems (INSP) Stock Analysis: Navigating the Sleep Apnea Market with High Valuation and Mixed Ratings

Inspire Medical Systems, Inc. (NYSE: INSP), a prominent player in the healthcare sector, is gaining attention for its innovative approach to treating obstructive sleep apnea (OSA) with its neurostimulation technology...

Cytokinetics, Incorporated (CYTK) Stock Analysis: Evaluating a Potential 43% Upside in the Biotech Sector

Cytokinetics, Incorporated (NASDAQ: CYTK) presents a compelling case for investors with its focus on pioneering muscle activators and inhibitors aimed at treating debilitating diseases. Despite recent challenges in its financial..

Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Biotechnology Innovator Seeks 28.67% Upside with Breakthrough Therapies

Rhythm Pharmaceuticals, Inc. (RYTM), a trailblazer in the biotechnology sector, is garnering attention for its innovative approaches to treating rare neuroendocrine diseases. With a market capitalization of $7.57 billion, the..

Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating the Upside Amidst Market Challenges

Bio-Rad Laboratories, Inc. (NYSE: BIO) is a stalwart in the healthcare sector, specifically within the medical devices industry, with a robust presence across the United States and internationally. With a..

BrightSpring Health Services, I (BTSG): Investor Outlook with a 34% Potential Upside

BrightSpring Health Services, Inc. (NYSE: BTSG) is making waves in the healthcare sector, particularly in the health information services industry. With a substantial market cap of $11.65 billion, the company..

Legend Biotech Corporation (LEGN): Investor Outlook on a Biotech Star with 125.70% Upside Potential

Legend Biotech Corporation (NASDAQ: LEGN) is making waves in the biotechnology sector with its innovative approach to cell therapies, particularly in oncology. This U.S.-headquartered company, founded in 2014, has been..

Search

Funds

US Broker Ratings

PPHE Hotel Group appoints Yoav Papouchado as Non-Executive Director

PPHE Hotel Group has appointed Yoav Papouchado as a non-executive director and said it will review the Board’s overall composition and balance...
Search

Funds

US Broker Ratings

FTSE 100

Funds